Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech’s disclosures can feel like a full-time job. Structure Therapeutics’ reports are packed with GPCR science, clinical trial nuances and dilution math that few investors have time to untangle. That’s why this page offers Structure Therapeutics SEC filings explained simply—so you can move past technical jargon and focus on the signals that matter.
Stock Titan’s AI reads every new document the moment it hits EDGAR and produces clear summaries you can trust. Need the Structure Therapeutics quarterly earnings report 10-Q filing translated into plain English? Wondering which risk factors changed in the latest 10-K? Our engine highlights R&D burn, cash runway and trial milestones in a click. You’ll also find real-time alerts for Structure Therapeutics Form 4 insider transactions real-time, giving you immediate insight into executive conviction. Looking for strategic shifts? The platform tags each Structure Therapeutics 8-K material events explained entry so you can understand partnership news or study results without combing through pages.
Use the table below to scan every form, from the Structure Therapeutics annual report 10-K simplified to the Structure Therapeutics proxy statement executive compensation. Track Structure Therapeutics insider trading Form 4 transactions, compare segments across quarters, and explore Structure Therapeutics earnings report filing analysis before making your next move. Whether you’re monitoring Structure Therapeutics executive stock transactions Form 4 or simply understanding Structure Therapeutics SEC documents with AI, our platform delivers all filings—plus AI-powered commentary—so you spend less time reading and more time deciding.
FMR LLC, identified as a 10% owner of Structure Therapeutics Inc. (GPCR), filed a Form 4 reporting an open-market sale on 07/30/2025.
- Securities sold: 26,310 American Depositary Shares (ADS), each representing three ordinary shares.
- Sale price: $17.87 per ADS, implying cash proceeds of roughly $470 k.
- Post-sale indirect holdings: 1,515,558 ADS plus 575,934 ordinary shares (45,120 held by F-Prime Capital Partners Life Sciences Advisors Fund VI LP and 530,814 held by F-Prime Capital Partners Life Sciences Fund VI LP).
- The filing notes that Abigail P. Johnson is a director, Chairman and CEO of FMR LLC and that members of the Johnson family collectively control 49% of FMR’s voting power.
No acquisitions were reported; the sole transaction was the ADS disposition coded “S.” FMR and its affiliated funds remain above the 10% beneficial-ownership threshold.
Structure Therapeutics (GPCR) Director Russell Angus C. received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 42,833 share options with the following key terms:
- Exercise price: $7.37 per share, based on fair market value of Ordinary Shares
- Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
- Full vesting: Prior to 2026 annual shareholder meeting
- Expiration date: June 22, 2035
- Each ADS (American Depositary Share) represents 3 Ordinary Shares
This equity compensation grant aligns with standard director compensation practices and demonstrates long-term commitment to the company. The 10-year exercise window provides significant time value for the options.
Structure Therapeutics (GPCR) director Ted W. Love received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 51,804 share options with the following key terms:
- Exercise price: $7.37 per share, based on ADS trading price
- Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
- Full vesting: Prior to 2026 annual shareholder meeting
- Expiration date: June 22, 2035
The options convert to ordinary shares, with each ADS representing three ordinary shares. This grant aligns the director's interests with shareholders through long-term equity compensation. The transaction was reported via Form 4 filing within the required timeframe, with signature by attorney-in-fact Jun Yoon on June 25, 2025.
FAQ
What is the current stock price of Structure Therapeutics ADR (GPCR)?
What is the market cap of Structure Therapeutics ADR (GPCR)?
